Patents by Inventor Paolo Salomoni

Paolo Salomoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of itch ubiquitinase activity
    Patent number: 9658229
    Abstract: The present invention relates to the identification of new drug targets for therapy of disorders including cancer. In particular, the present invention relates to inhibition of the E3 ubiquitin ligase, Itch, as a means for treating disorders. Furthermore, the present invention relates to the regulation of p63 and p73 stability in cells. In particular, the invention relates to the modulation of the regulation of p63 and p73 stability in cells through modulation of the expression or activity of Itch. Moreover, the invention relates to the use of Itch as a target for the development of agents capable of modulating p63 or p73 stability and especially agents capable of modulating the interaction of Itch and p63 and p73. Such agents may be useful in therapeutic applications including cancer treatment and modulation of skin differentiation.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: May 23, 2017
    Assignee: RYBOQUIN COMPANY LIMITED
    Inventors: Gennaro Melino, Marlo Rossi, Paolo Salomoni
  • Modulators of Itch Ubiquitinase Activity
    Publication number: 20160084838
    Abstract: The present invention relates to the identification of new drug targets for therapy of disorders including cancer. In particular, the present invention relates to inhibition of the E3 ubiquitin ligase, Itch, as a means for treating disorders. Furthermore, the present invention relates to the regulation of p63 and p73 stability in cells. In particular, the invention relates to the modulation of the regulation of p63 and p73 stability in cells through modulation of the expression or activity of Itch. Moreover, the invention relates to the use of Itch as a target for the development of agents capable of modulating p63 or p73 stability and especially agents capable of modulating the interaction of Itch and p63 and p73. Such agents may be useful in therapeutic applications including cancer treatment and modulation of skin differentiation.
    Type: Application
    Filed: April 23, 2015
    Publication date: March 24, 2016
    Inventors: Gennaro Melino, Marlo Rossi, Paolo Salomoni
  • Modulators of Itch ubiquitinase activity
    Patent number: 9051572
    Abstract: The present invention relates to the identification of new drug targets for therapy of disorders including cancer. In particular, the present invention relates to inhibition of the E3 ubiquitin ligase, Itch, as a means for treating disorders. Furthermore, the present invention relates to the regulation of p63 and p73 stability in cells. In particular, the invention relates to the modulation of the regulation of p63 and p73 stability in cells through modulation of the expression or activity of Itch. Moreover, the invention relates to the use of Itch as a target for the development of agents capable of modulating p63 or p73 stability and especially agents capable of modulating the interaction of Itch and pq63 or p73. Such agents may be useful in therapeutic applications including cancer treatment and modulation of skin differentiation.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: June 9, 2015
    Assignee: RYBOQUIN COMPANY LIMITED
    Inventors: Gennaro Melino, Mario Rossi, Paolo Salomoni
  • Modulators of Itch Ubiquitinase Activity
    Publication number: 20090306187
    Abstract: The present invention relates to the identification of new drug targets for therapy of disorders including cancer. In particular, the present invention relates to inhibition of the E3 ubiquitin ligase, Itch, as a means for treating disorders. Furthermore, the present invention relates to the regulation of p63 and p73 stability in cells. In particular, the invention relates to the modulation of the regulation of p63 and p73 stability in cells through modulation of the expression or activity of Itch. Moreover, the invention relates to the use of Itch as a target for the development of agents capable of modulating p63 or p73 stability and especially agents capable of modulating the interaction of Itch and p63 or p73. Such agents may be useful in therapeutic applications including cancer treatment and modulation of skin differentiation.
    Type: Application
    Filed: January 19, 2006
    Publication date: December 10, 2009
    Applicant: Medical Research Council
    Inventors: Gennaro Melino, Marlo Rossi, Paolo Salomoni